Welcome to our dedicated page for Nuwellis SEC filings (Ticker: NUWE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission (SEC) filings for Nuwellis, Inc. (Nasdaq: NUWE), a medical technology and medical device company focused on precision fluid management for patients with cardio-renal conditions and fluid overload. Through these filings, investors can review how Nuwellis reports its financial performance, material events, and key developments related to its Aquadex SmartFlow® ultrafiltration system and its Vivian™ pediatric continuous renal replacement therapy (CRRT) platform in development.
Current report filings (Form 8-K) for Nuwellis often cover topics such as quarterly financial results, changes in executive roles, new patents, NIH grant-supported programs, FDA 510(k) clearances for accessories like catheters, and at-the-market equity offering agreements. Some 8-K filings also reference press releases announcing clinical registry findings, such as the ULTRA-Peds pediatric Aquadex registry, or new intellectual property supporting pediatric safety features and hemolysis sensing in extracorporeal circuits.
Annual reports on Form 10-K and quarterly reports on Form 10-Q (when available) provide more detailed discussions of Nuwellis’ business, including its focus on fluid overload, its Aquadex SmartFlow system, development-stage technologies like Vivian, and its geographic footprint with headquarters in Minneapolis and a subsidiary in Ireland. These filings also describe risk factors, liquidity, capital-raising activities, and other information relevant to NUWE shareholders.
Stock Titan’s platform enhances these SEC documents with AI-powered summaries that explain the key points of lengthy filings, highlight important changes from prior periods, and help users quickly understand complex disclosures. Investors can also use this page to follow real-time updates as new Nuwellis filings are posted to EDGAR, including current reports, registration statements, and other material submissions related to NUWE.
Nuwellis has received a delisting notice from Nasdaq on June 18, 2025, due to non-compliance with the minimum bid price requirement of $1.00 for 30 consecutive trading days. The company is not eligible for the standard compliance period due to previous reverse stock splits.
Key developments:
- Company executed a reverse stock split on June 27, 2024
- Shareholders approved a new reverse split ratio of 1-for-5 to 1-for-70 at May 20, 2025 annual meeting
- Board intends to implement another reverse stock split to regain compliance
- Company plans to request a hearing with Nasdaq Hearings Panel
Stock will remain listed on Nasdaq Capital Market pending the hearing outcome. However, there is no guarantee of continued listing or successful compliance restoration. This situation presents significant risks for investors, including potential delisting and further share dilution through another reverse split.